… as a steady-state trough concentration of 15–20 mg/L [13]. … or included a dose cap in obesity.
In situations where the supporting … only recommends continuous infusion in patients with …

… target of meropenem efficacy was set at a steady state … decrease for piperacillin-tazobactam
in 44% of patients [29]. … ; BMI, body mass index; BSI, bloodstream infection; Css, meropenem …

… when prolonged infusions are administered to justify the use of the SDD category for PTZ
against Enterobacterales. CLSI has applied the SDD designation to cefepime, ceftaroline, …

… 0.73, at steady state, for both modes of infusion and whatever … daily in continuous infusion
in critically ill patients in various … PTA of temocillin in obese (BMI > 30) critically ill patients (25). …

… Average steady-state meropenem concentrations (C ss ) were calculated and the C ss /MIC
ratio was selected as a pharmacodynamic parameter of meropenem efficacy. The C ss /MIC …

… before dose administration (C ss , or steady-state plasma … prolonged infusion of
piperacillin/tazobactam and meropenem in critically ill patients associated with improved …

… exposure of steady state piperacillin concentrations (c PIP ) … There was no significant
association with c PIP , age or BMI. … continuous infusion in this study, 49 and 99% of the patients …

… Critically ill patients show several characteristics (eg, sepsis, renal impairment or conversely
… alter beta-lactam pharmacokinetics (PK) in comparison with non-critically ill patients. This …

… To predict steady-state antibiotic exposure, Bayesian forecasting was … Therefore, in overweight
or obese patients with normal or … that the use of prolonged or continuous infusion of beta-…

… administration time into prolonged or continuous infusions to … dose once the patient had
reached steady-state, or before the … Obese patients may also receive doses up to this maximum, …